Category survey

HERMOSTON RAPPEUMASAIRAUKSIEN IMMUNOLOGISEEN SÄÄTELYYN PERUSTUVAT PIENMOLEKYYLIT. Nerve degeneration diseases immunologically BASED ON REGULATORY small molecules Investments < €500k Finland 2016    

Targeting Alpha-Synuclein for Treating Multiple System Atrophy Investments < €500k France 2016    

The 5-HT4 receptor networks: bodyguards of ADAM10 and APP trafficking Investments < €500k France 2016    

Click strategies for multifunctional anti-Alzheimer agents Investments < €500k France 2016    

NeuroInflammation and Cognitive decline in Alzheimer’s Disease : a pilot study of PET imaging of the translocator proteine ligands (TSPO) with [18 F] DPA-714 (NICAD) Investments < €500k France 2016    

Modulation of Perceived Duration by Contextual (Motion) and Dopaminergic Factors: An Integrated Psychophysical, Functional Imaging, Electrophysiological, and Psychopharmacological Approach Investments < €500k France 2016    

A2A receptors and Tauopathy Investments < €500k France 2016    

Oxidation of the amyloid beta peptide and implications in the etiology of Alzheimer’s Disease Investments < €500k France 2016    

Role of Cyp46 in cholesterol metabolism and neuroprotection in Huntington’s Disease Investments < €500k France 2016    

Deciphering stress-induced immune alterations and their contribution to physiopathological mechanisms in Parkinson’s disease. Investments < €500k France 2016    

Modulating Ire1 to treat Parkinson’s Disease Investments < €500k France 2016    

AGING, LIPIDIC HOMEOSTASIS AND INFLAMMATION IN EXPERIMENTAL PARKINSONISM. EFFECT OF TREATMENT WITH FASUDIL AND / OR WITH PIOGLITAZONE. Investments < €500k Spain 2016    

INTERACTIONS OF REELINE / APOE AND ALTERNATIVE LIGANDS WITH ß-AMYLOID, ITS DISFUNCTION IN ALZHEIMER’S DISEASE Investments < €500k Spain 2016    

STUDY OF THE EFFECT OF THE DECREASE OF ß-GALACTOSIDASE AND THE CONSEQUENTIAL INCREASE OF GANGLIOSIDE GM1 IN NEURONES ON THE PRODUCTION AND AGGREGATION OF ß-AMYLOID PEPTIDE* Investments < €500k Spain 2016    

Synaptic circuit protection in AD and HD: BDNF/TrkB and Arc signaling as rescue factors Investments < €500k Finland 2016    

Neuroprotective microRNAs, trophic factors and ER stress in adult dopaminergic neurons: significance for Parkinson’s disease Investments < €500k Finland 2016    

The role of Prolyl oligopeptidase (POP) and its inhibition on α-synuclein aggregation and Parkinson’s disease models Investments < €500k Finland 2016    

Biology and Mode of Action of Novel Neurotrophic Factors CDNF and MANF Investments < €500k Finland 2016    

Clinical trials network for preventing dementia and Alzheimer’s disease Investments < €500k Finland 2016    

Multimodal analysis of Imaging and Biomarkers in Alzheimer’s disease Investments < €500k Finland 2016    

Regulation of neuroinflammation in Alzheimer’s disease by non-coding RNAs Investments < €500k Finland 2016    

The role of Prolyl oligopeptidase (POP) and its inhibition on α-synuclein aggregation and Parkinson’s disease models Investments < €500k Finland 2016    

Singing and Playing in the Recovering and Degenerating Brain: Efficacy and Neural Mechanisms of Music in Stroke, Brain Injury, and Alzheimer’s Disease Investments < €500k Finland 2016    

Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability Investments < €500k Finland 2016    

Dementia and interaction – intersections between research and communication training Investments < €500k Finland 2016    

Fingerprinting the risk of dementia and likelihood of intervention response to facilitate prevention-related decision-making Investments < €500k Finland 2016    

3’UTR -based regulation of neurotrophic factors as a novel tool to understand neuronal function and find treatment for Parkinson’s disease Investments < €500k Finland 2016    

Using novel 3’UTR targeting based approaches to study gene function and treat neurodegenerative disease Investments < €500k Finland 2016    

Distinct nicotinic acetylcholine receptors in dorsal and ventral striatum: Basis for novel therapies of Parkinson’s disease Investments < €500k Finland 2016    

Transmitophagy: the key to aging and neurodegeneration? Investments < €500k Finland 2016    

C / EBPS MICROGLIALES AS DOTH THERAPEUTIC POTENTIAL IN PARKINSON’S DISEASE Investments < €500k Spain 2016    

SINUCLEINAS, DEPRESSION AND PARKINSON DISEASE. NEW THERAPEUTIC STRATEGIES BASED ON NUCLEIC ACIDS OF INTERFERENCE Investments < €500k Spain 2016    

STEP REGULATION BY BDNF: THERAPEUTIC IMPLICATIONS IN NEUROLOGICAL DISEASES Investments < €500k Spain 2016    

NANOPARTICLE ACCESS FACILITATION SYSTEMS IN NEURODEGENERATIVE DISORDERS (NANOPARTICLE DELIVERY SYSTEM FOR NEURODEGENERATIVE DISORDERS) Investments < €500k Spain 2016    

THE NERVOUS SYSTEM AUTONOMO ENTERICO AS BIOMARCADOR PRECOZ IN THE DISEASE OF PARKINSON Investments < €500k Spain 2016    

INTERACTOMES AND MARKERS TO DISCRIMINATE REGIONAL NEURONAL VULNERABILITY FACTORS IN NEURODEGENERATION ASSOCIATED WITH NORMAL AND PATHOLOGICAL AGING IN THE CNS. Investments < €500k Spain 2016    

OXIDATIVE STRESS AND INFLAMMATION IN THE EVOLUTION OF THE PROCESS OF AGING AND PROGRESSION OF ALZHEIMER’S DISEASE IN DIFFERENT REGIONS OF THE CENTRAL HUMAN NERVOUS SYSTEM Investments < €500k Spain 2016    

DEVELOPMENT OF NEW THERAPEUTIC STRATEGIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY: REGULATION OF AUTOPHAGIA AND INTRACELLULAR SIGNALING WAYS. Investments < €500k Spain 2016    

IMPACT OF COENZYME Q10 (UBIQUINOL) IN THE COMMITMENT OF VASCULAR BRAIN ENDOTHELIUM IN THE COGNITIVE DETERIORATION: FUNCTIONAL AND METABOLIC VALUATION IN VIVO AND IN VITRO. Investments < €500k Spain 2016    

VASCULAR DYSFUNCTION AND FRAGILITY A CAUSAL RELATIONSHIP OF IDA AND RETURN WITH END OF TRIP IN THE DEMENTIA? Investments < €500k Spain 2016    

MOLECULAR STUDY AND GENE THERAPY FOR MUCOPOLISACARIDOSIS TYPE VII. Investments < €500k Spain 2016    

EFFECTIVENESS AND SAFETY OF A FRAGMENT OF BAPINEUZUMAB AS A THERAPY OF ALZHEIMER’S DISEASE IN A MURINO MODEL. IMPLICATION OF APOLIPOPROTEINS IN CLARIFICATION Investments < €500k Spain 2016    

THYROSAINE KINASE ACK1 IN NEURODEGENERATION AND NEURONAL DEATH Investments < €500k Spain 2016    

EVALUATING MICROGLIAL AND ASTROGLIAL DYSFUNCTION AS THE BASIS OF NEURODEGENERATIVE PROCESS AND DEMENTIA IN ALZHEIMER’S DISEASE: NEW THERAPEUTIC APPROACHES. Investments < €500k Spain 2016    

EFFICIENT PREVENTION OF DEMENTIA IN SUBJECTS WITH HIGH RISK. Investments < €500k Spain 2016    

JNK1, A THERAPEUTIC DIAL POTENTIAL IN ALZHEIMER’S DISEASE Investments < €500k Spain 2016    

NEUROPROTECTION MECHANISMS THROUGH THE MODULATION OF CANNINOIN ENDOGENES IN PARKINSON’S DISEASE Investments < €500k Spain 2016    

EVALUATING MICROGLIAL AND ASTROGLIAL DYSFUNCTION AS A BASIS OF THE NEURODEGENERATIVE PROCESS IN ALZHEIMER’S DISEASE: NEW THERAPEUTIC APPROACHES Investments < €500k Spain 2016    

MITOCHONDRIAL PHARMACOGENOMIC IN ALZHEIMER’S DISEASE Investments < €500k Spain 2016    

STUDY OF BIOMARKERS IN THE CONTINUOUS PATHOLOGICAL EXISTING BETWEEN LATERAL AMIOTROPHIC SCLEROSIS (ELA) AND FRONTOTEMPORAL LOBULAR DEGENERATION (DLFT) -II Investments < €500k Spain 2016